

OriGene Technologies Inc.


9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES Phone: +1-858-888-7900 Fax: +1-858-888-7904 <u>US-info@acris-antibodies.com</u>

PA1163 OriGene EU

Acris Antibodies GmbH Schillerstr. 5 32052 Herford GERMANY Phone: +49-5221-34606-0 Fax: +49-5221-34606-11 info@acris-antibodies.com

| | Recombinant Human MIG (CXCL9) |
|-----------------------|--|
| Alternate names: | CXCL9 |
| Catalog No.: | PA1163 |
| Quantity: | 5 µg |
| Concentration: | 1 mg/ml |
| Background: | CXCL9 is a chemoattractant for activated T cells and possess angiostatic activity. Both CXCL9 and CXCL10 have been considered as important components for the anti-tumour activities of interferon-gamma (IFNgamma) and interleukin-12 in animal models. HuMIG is induced in THP-1 cells and in peripheral blood mononuclear cells by interferon-gamma but not by interferon-alpha or by lipopolysaccharide. Analysis of mouse and human genomic DNAs suggested that the Mumig and Humig genes are true mouse-human homologues. |
| Species: | Human |
| Source: | E. coli, E.coli |
| Format: | State: Sterile Filtered White lyophilized (freeze-dried) powder. Purity: >98% Greater than 95.0% as determined by: (a) Analysis by RP-HPLC. (b) Anion-exchange FPLC. (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained. Buffer System: Lyophilized from a concentrated solution in water containing no additives. Endotoxin Level: Less than 0.1 ng/µg (IEU/µg) of Human MIG. Dimers: Less than 1% as determined by silver-stained SDS-PAGE gel analysis. Reconstitution: It is recommended to reconstitute the lyophilized MIG in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions. |
| Description: | Recombinant Human MIG (monokine induced by gamma-interferon) produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 103 amino acids. Recombinant Human MIG is purified by proprietary chromatographic techniques. AA Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be, Thr-Pro-Val-Val-Arg. Biological Activity: ED50 range= 10.0-100.0 ng/mL, determined by the dose dependent chemotaxis with human lymphocytes cultured in the presence of IL-2. The optimal concentration for each specific application should be determined by an initial dose response assay. Molecular weight: 11700 Dalton. Molecular weight: 12 kDa |
| Add. Information: | Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280 nm . 2. Analysis by RP-HPLC, using a calibrated solution of Human MIG as a Reference Standard. |

For research and in vitro use only. Not for diagnostic or therapeutic work. Material Safety Datasheets are available at www.acris-antibodies.com or on request.





OG/20130513



PA1163: Recombinant Human MIG (CXCL9)

Storage:Lyophilized MIG although stable at room temperature for 3 weeks, should be stored
desiccated below -180C. Upon reconstitution MIG should be stored at 40C between 2-7
days and for future use below -180C. For long term storage it is recommended to add a
carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

General Readings: 1. Egesten A, Eliasson M, Johansson HM, Olin AI, Morgelin M, Mueller A, et al. The CXC chemokine MIG/CXCL9 is important in innate immunity against Streptococcus pyogenes. J Infect Dis. 2007 Mar 1;195(5):684-93. Epub 2007 Jan 18. PubMed PMID: 17262710.
2. Levy-Strumpf N, Culotti JG. VAB-8, UNC-73 and MIG-2 regulate axon polarity and cell migration functions of UNC-40 in C. elegans. Nat Neurosci. 2007 Feb;10(2):161-8. Epub 2007 Jan 21. PubMed PMID: 17237777.

3. Wu M, Herman MA. Asymmetric localizations of LIN-17/Fz and MIG-5/Dsh are involved in the asymmetric B cell division in C. elegans. Dev Biol. 2007 Mar 15;303(2):650-62. Epub 2006 Dec 15. PubMed PMID: 17196955.


4. Ranjbaran H, Wang Y, Manes TD, Yakimov AO, Akhtar S, Kluger MS, et al. Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation. 2006 Sep 19;114(12):1293-300. Epub 2006 Aug 28. PubMed PMID: 16940188.

5. Zhang R, Tian L, Xiao F, Wen YJ, li J, Hou JM, et al. [Construction of pORF-mIG and activity evaluation of MIG in vitro]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Jul;37(4):502-5. PubMed PMID: 16909588.

6. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 2007 Jan 11;26(2):269-76

Pictures:

PA1163ME0607





OG/20130513